Abbott Laboratories (ABT) Notes Payables (2009 - 2021)

Abbott Laboratories has disclosed Notes Payables across 13 years of filings, most recently posting $197.0 million for Q3 2021.

• In Q3 2021, Notes Payables fell 5.29% year-over-year to $197.0 million; the TTM figure through Sep 2021 stood at $197.0 million (down 5.29% YoY), while the FY2020 annual figure was $213.0 million, up 5.97% from the prior year.
• Notes Payables came in at $197.0 million for Q3 2021 at Abbott Laboratories, down from $199.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $341.0 million in Q2 2018 to a low of $197.0 million in Q3 2021.
• Average Notes Payables over 5 years is $213.6 million, with a median of $205.0 million recorded in 2020.
• Year-over-year, Notes Payables plunged 92.46% in 2017 and jumped 56.42% in 2018.
• Over 5 years, Notes Payables stood at $206.0 million in 2017, then slipped by 2.91% to $200.0 million in 2018, then increased by 0.5% to $201.0 million in 2019, then rose by 5.97% to $213.0 million in 2020, then decreased by 7.51% to $197.0 million in 2021.
• Per Business Quant data, the three most recent Notes Payables figures were $197.0 million in Q3 2021, $199.0 million in Q2 2021, and $199.0 million in Q1 2021.